Ignite Creation Date:
2026-03-26 @ 3:20 PM
Ignite Modification Date:
2026-03-31 @ 8:59 PM
Study NCT ID:
NCT07444918
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-03
First Post:
2026-02-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2026-03-25'}, 'conditionBrowseModule': {'meshes': [{'id': 'D012008', 'term': 'Recurrence'}, {'id': 'D012208', 'term': 'Rhabdomyosarcoma'}, {'id': 'D012512', 'term': 'Sarcoma, Ewing'}, {'id': 'D012516', 'term': 'Osteosarcoma'}], 'ancestors': [{'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D009217', 'term': 'Myosarcoma'}, {'id': 'D009379', 'term': 'Neoplasms, Muscle Tissue'}, {'id': 'D018204', 'term': 'Neoplasms, Connective and Soft Tissue'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D012509', 'term': 'Sarcoma'}, {'id': 'D018213', 'term': 'Neoplasms, Bone Tissue'}, {'id': 'D009372', 'term': 'Neoplasms, Connective Tissue'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C584112', 'term': 'irinotecan sucrosofate'}, {'id': 'D014750', 'term': 'Vincristine'}, {'id': 'D000077204', 'term': 'Temozolomide'}], 'ancestors': [{'id': 'D014748', 'term': 'Vinca Alkaloids'}, {'id': 'D046948', 'term': 'Secologanin Tryptamine Alkaloids'}, {'id': 'D026121', 'term': 'Indole Alkaloids'}, {'id': 'D000470', 'term': 'Alkaloids'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D007211', 'term': 'Indoles'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D054836', 'term': 'Indolizidines'}, {'id': 'D007212', 'term': 'Indolizines'}, {'id': 'D003606', 'term': 'Dacarbazine'}, {'id': 'D014226', 'term': 'Triazenes'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D007093', 'term': 'Imidazoles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 33}}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2026-03-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2026-02', 'completionDateStruct': {'date': '2032-06-06', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2026-03-02', 'studyFirstSubmitDate': '2026-02-05', 'studyFirstSubmitQcDate': '2026-03-02', 'lastUpdatePostDateStruct': {'date': '2026-03-03', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2026-03-03', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-12-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Objective Response Rate (ORR)', 'timeFrame': 'At Week 6, Week 12, Week 18, and every 6 weeks thereafter until treatment discontinuation (up to approximately 6 months)'}], 'secondaryOutcomes': [{'measure': 'Disease Control Rate (DCR)', 'timeFrame': 'At Week 6, Week 12, Week 18, and every 6 weeks thereafter until treatment discontinuation (up to approximately 6 months)'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'From treatment initiation until death, up to 5 years of follow-up.'}, {'measure': 'Progression-Free Survival (PFS)', 'timeFrame': 'From treatment initiation until progression/death, up to 5 years of follow-up.'}, {'measure': 'Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'timeFrame': 'From first dose of study treatment until 30 days after the last dose (up to approximately 6 months)'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Pediatric patients Relapsed refractory malignant solid tumors Neuroblastoma Rhabdomyosarcoma Ewing sarcoma Osteosarcoma Liposomal irinotecan'], 'conditions': ['Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)']}, 'descriptionModule': {'briefSummary': 'This is a prospective, single-center, single-arm interventional trial conducted at Tianjin Medical University Cancer Institute and Hospital. It evaluates the efficacy and safety of a combination regimen (liposomal irinotecan + vincristine + temozolomide ± anlotinib) in children with relapsed or refractory malignant solid tumors, with the goal of optimizing regimen-related adverse reactions and exploring appropriate administration strategies.\n\n1. Study Objectives Primary Objective: Assess the objective response rate (ORR) of the combination regimen in the study population.\n\n Secondary Objectives: Evaluate survival outcomes (progression-free survival \\[PFS\\], overall survival \\[OS\\]) and the incidence of adverse events (per NCI CTCAE v5.0).\n2. Eligibility Criteria Inclusion Criteria Aged 3-18 years (inclusive) at consent; Pathologically confirmed relapsed or refractory malignant solid tumors (e.g., neuroblastoma, rhabdomyosarcoma); At least one measurable lesion (per RECIST v1.1); Adequate functional status and organ function (per institutional standards); Written informed consent from subject/legal guardian. Exclusion Criteria Hypersensitivity to study drugs; Active uncontrolled infection or severe comorbidities; Concurrent participation in other interventional trials; Conditions precluding study participation (per investigator judgment).\n3. Intervention Procedures\n\n Eligible subjects are assigned to short-course or long-course subgroups based on clinical status:\n\n Short-course: Liposomal irinotecan (Day 1), vincristine (Day 1), temozolomide (Days 1-5), ± weight-based anlotinib (Days 1-14); Long-course: Liposomal irinotecan (Days 1/8/15), plus the same doses of other drugs as the short-course subgroup.\n\n Each treatment cycle is 21 days. Efficacy is assessed regularly; treatment (dose/subgroup) will be adjusted per clinical condition.\n4. Outcome Assessments Primary Outcome: ORR (assessed per RECIST v1.1 at regular intervals); Secondary Outcomes: PFS, OS (long-term follow-up post-treatment), and adverse event incidence.\n5. Participant Requirements Participation is voluntary. Subjects/guardians must provide written informed consent prior to enrollment. Long-term follow-up will be conducted post-treatment.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '18 Years', 'minimumAge': '3 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Aged 3 to 18 years (inclusive) at the time of informed consent signing.\n* Pathologically confirmed relapsed or refractory malignant solid tumors (including but not limited to neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, osteosarcoma).\n* At least one measurable lesion (as defined by RECIST v1.1) confirmed by CT/MRI within 28 days prior to enrollment.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.\n* Adequate organ function (absolute neutrophil count ≥1.5×10⁹/L; platelet count ≥100×10⁹/L; hemoglobin ≥90g/L; serum creatinine ≤1.5×upper limit of normal \\[ULN\\] for age; total bilirubin ≤1.5×ULN; alanine aminotransferase/aspartate aminotransferase ≤2.5×ULN, or ≤5×ULN if liver metastasis exists).\n* Written informed consent provided by the subject (if ≥18 years old) or legal guardian (if \\<18 years old).\n\nExclusion Criteria:\n\n* Known hypersensitivity to any component of the study drugs (liposomal irinotecan, vincristine, temozolomide, anlotinib).\n* Active systemic infection requiring systemic antibiotic treatment within 7 days prior to enrollment.\n* History of severe cardiovascular disease (e.g., congestive heart failure, uncontrolled arrhythmia).\n* Concurrent participation in another interventional clinical trial.\n* Pregnancy, lactation, or unwillingness to use effective contraception (for sexually active subjects).\n* Other medical conditions that, in the investigator's judgment, may affect study participation or outcome assessment."}, 'identificationModule': {'nctId': 'NCT07444918', 'briefTitle': 'Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors', 'organization': {'class': 'OTHER', 'fullName': 'Tianjin Medical University Cancer Institute and Hospital'}, 'officialTitle': 'A Prospective, Single-Center, Single-Arm Study to Evaluate the Efficacy and Safety of Liposomal Irinotecan, Vincristine, and Temozolomide With or Without Anlotinib in Children and Adolescents With Relapsed or Refractory Malignant Solid Tumors', 'orgStudyIdInfo': {'id': 'CSPC-DNY-MST-TJ01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Liposomal Irinotecan + Vincristine + Temozolomide ± Anlotinib (Short/Long Course)', 'description': 'Combination regimen of liposomal irinotecan, vincristine, and temozolomide (with optional anlotinib, dose based on body weight). Subjects are assigned to 2 subgroups by clinical status: short-course (liposomal irinotecan on Day 1) or long-course (liposomal irinotecan on Days 1/8/15). Other drugs follow the same dosing schedule across subgroups; treatment adjustments are made per clinical condition.', 'interventionNames': ['Drug: Liposomal Irinotecan, Vincristine, Temozolomide, and Optional Anlotinib']}], 'interventions': [{'name': 'Liposomal Irinotecan, Vincristine, Temozolomide, and Optional Anlotinib', 'type': 'DRUG', 'description': 'This is a combination chemotherapy regimen for children (3-18 years old) with relapsed or refractory malignant solid tumors. It includes liposomal irinotecan, vincristine, and temozolomide, with optional anlotinib (dose adjusted by body weight: 8mg/day for \\<35kg; 12mg/day for ≥35kg). Administration is divided into short-course (liposomal irinotecan on Day 1) and long-course (liposomal irinotecan on Days 1/8/15) subgroups; other drugs follow the same dosing schedule across subgroups. Each treatment cycle lasts 21 days, and adjustments are made based on clinical conditions.', 'armGroupLabels': ['Liposomal Irinotecan + Vincristine + Temozolomide ± Anlotinib (Short/Long Course)']}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'De-identified individual participant data (IPD) including demographic characteristics, treatment subgroup assignment (short/long course), efficacy outcomes (ORR, PFS, OS assessments per protocol), and safety data (adverse event records graded by NCI CTCAE v5.0) will be shared. All personally identifiable information (e.g., name, medical record numbers) will be removed to protect participant privacy. IPD sharing will be allowed after primary endpoint analysis (or study result publication), upon formal request by qualified researchers for legitimate medical research purposes, and subject to institutional review board (IRB) approval plus a signed data use agreement (DUA) (outlining data security/responsible use).'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Tianjin Medical University Cancer Institute and Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}